ライフサイエンスコーパス: disease status

1 with the Mantel-Haenszel test stratified by disease status.

2 atin C well matched follow-up chronic kidney disease status.

3 ial neoplasia grade 2 or higher [CIN2+]) for disease status.

4 ts that show significant association with AD disease status.

5 levels in skeletal muscle and differentiate disease status.

6 ubgroups according to concomitant autoimmune disease status.

7 rhood SNPs show statistical association with disease status.

8 ulin use, renal function, and cardiovascular disease status.

9 early PD from healthy subjects and evaluate disease status.

10 e of relapse and provided a better marker of disease status.

11 was used in a multivariate model to predict disease status.

12 supporting their remarkable contributions to disease status.

13 microbiome was not significantly affected by disease status.

14 .28 ng/mL were independently associated with disease status.

15 and Clostridiales, correlates strongly with disease status.

16 that were stratified by baseline periodontal disease status.

17 se of a radiosensitizing platinum agent, and disease status.

18 ve similar phenotypic effects independent of disease status.

19 2 and FLT3 aberrant splicing correlated with disease status.

20 capacity and positively with atherosclerotic disease status.

21 tes, and high expression was correlated with disease status.

22 02) were associated with twin discordance in disease status.

23 uminate changes relevant to pathogenesis and disease status.

24 on with the elevation of IL-1beta levels and disease status.

25 be useful as a minimally invasive marker of disease status.

26 most of the microbiome samples clustered by disease status.

27 national Staging System and minimal residual disease status.

28 nic Obstructive Lung Disease stage, and COPD disease status.

29 teria in Solid Tumors were applied to assess disease status.

30 ments being the most sensitive to changes in disease status.

31 two existing classifications of periodontal disease status.

32 can provide a continually updated record of disease status.

33 ividuals (n = 469) and the correlations with disease status.

34 ance on predicting both cognitive scores and disease status.

35 and can be regarded as an indirect effect to disease status.

36 Oligomeric Abeta was not a predictor of disease status.

37 stratified for hormone receptor and visceral disease status.

38 or early-stage diagnostics and monitoring of disease status.

39 0 and MMP-9 are associated with radiographic disease status.

40 both circulating 25(OH)D concentrations and disease status.

41 or qualitatively to the patients' autoimmune disease status.

42 the activation parameters assessed, and the disease status.

43 es in environment or according to health and disease status.

44 ay serve as a clinically useful indicator of disease status.

45 identify variable interactions predictive of disease status.

46 lk may be useful as meaningful indicators of disease status.

47 and calcium supplements affects periodontal disease status.

48 ogic examination by a neurologist blinded to disease status.

49 Children were grouped according to disease status.

50 lipid profile that predicted coronary artery disease status.

51 ic regression, allowing for interaction with disease status.

52 ctional and used self-reported insurance and disease status.

53 cellular and cf mtDNA content is affected by disease status.

54 are predictive of a given phenotype, such as disease status.

55 ir specific microenvironment, treatment, and disease status.

56 F levels of the biomarker can be affected by disease status.

57 AdNet were very informative about the cancer disease status.

58 and other anatomic and functional markers of disease status.

59 cantly in abundance according to periodontal disease status.

60 associations between microbial elements and disease status.

61 ween progression of differentiation and FSHD disease status.

62 step reference standard approach to estimate disease status.

63 ral disease rely upon indices that summarize disease status.

64 and are important covariates for DEA across disease status.

65 Randomisation was stratified by visceral disease status.

66 G) ranging from health to severe periodontal disease status.

67 that it may be a clinically useful marker of disease status.

68 as the alterations of fractal pattern during diseased statuses.

69 2.174-3.636; P < .001), HIV rather than AIDS disease status (1.377; 1.049-1.808; P = .02), and HIV cl

70 On the basis of investigators' assessment of disease status, 163 of 169 (96%) analysable patients in

71 treous bands on imaging correlated with plus disease status (29% vs. 5% without bands; P = 0.05).

72 3) in CSF allowed for reliable prediction of disease status 3 years from the time of sample collectio

73 fering in abundance according to periodontal disease status, 53% had multiple oligotypes appearing to

74 DG PET to rank and localize single subjects' disease status according to PD-typical (PD vs. controls)

75 with 10.1% of patients losing their definite disease status, accurate determination of variant pathog

76 to basophil degranulation phenotypes and to disease status (active or inactive).

77 y was a strong inverse predictor of coronary disease status (adjusted odds ratio for coronary disease

78 patients attaining negative minimal residual disease status after remission induction, minimal residu

79 ith a permuted block procedure stratified by disease status, age, and geographical location.

80 uch as body mass, age, social group size and disease status, all potentially influence energy balance

81 by each microbiota were predictive of human disease status and accounted for disease severity in the

82 n involvement and disease morbidity, current disease status and activity, past and current medication

83 nd adiponectin with mammographic density and disease status and assessed their prognostic effect on r

84 tudy we did not observe correlations between disease status and autophagic or lysosomal markers.

85 us factors such as cell type, cell cycle, or disease status and can change in response to a biochemic

86 tegies to further improve outcomes, although disease status and center expertise remain key component

87 evaluated the relationship between change in disease status and change in CRP using nonparametric tes

88 Investigator-determined disease status and clinical benefit were assessed every

89 apy-related or de-novo AML when adjusted for disease status and cytogenetics.

90 Vizsla pedigree dogs were stratified both on disease status and degree of relatedness to an affected

91 s not independent of age or minimal residual disease status and did not seem to be driven by an incre

92 bal DNA methylation status as a biomarker of disease status and exposure to environmental toxicants,

93 odels the distribution of the test SNP given disease status and flanking marker genotypes.

94 ygous mutations in PGM3 that segregated with disease status and followed recessive inheritance.

95 te the relationship of eRNA transcription to disease status and how genetic variants alter enhancer t

96 ligation that was independent of HLA, AA, or disease status and included elevated plasma IL-1alpha, I

97 continuous variable, can be used to monitor disease status and might be useful as an intermediate en

98 ble, non-invasive technique to differentiate disease status and might provide a means to monitor and

99 clinical trials that are designed to assess disease status and prevent progression to cirrhosis, liv

100 e a promising diagnostic tool for monitoring disease status and prognostication of NPC patients.

101 g a relatively non-invasive means to monitor disease status and response to therapies.

102 Periodontal disease status and salivary cytokine levels were measure

103 (pNFH) in cerebrospinal fluid (CSF) predict disease status and survival in c9ALS patients, and are l

104 Marker levels were correlated to disease status and survival.

105 se models of neuromuscular disease to assess disease status and the effects of therapy.

106 light opportunities for improvement of their disease status and to evaluate their visual acuity (VA)

107 us provide important clinical information on disease status and treatment efficacy in MS patients.

108 at baseline that controlled fully for basal disease status and treatment, the association of anger a

109 confounding factors including heart failure disease status and used the G-SCI (Genotype-independent

110 ssion was used to explore the association of disease status and various patient- and implant-related

111 riant (c.1907 G>A) in RBM20, segregated with disease status and was absent in unaffected internal ref

112 ee that are associated with covariates (e.g. disease status); and (iii) assess the overall associatio

113 Younger age, latent disease status, and access to care at a regional center

114 xtension collecting annual data on survival, disease status, and adverse events.

115 Aggregated data per patient, disease status, and available measurements were assessed

116 associated with biological factors, such as disease status, and environmental factors, such as smoki

117 an ICD to 148 controls matched for age, sex, disease status, and family.

118 , and 10, leukocyte telomere length, chronic disease status, and frailty.

119 perform before and after treatment to assess disease status, and how to interpret the test results an

120 neuroimaging measures, cognitive scores and disease status, and ignore the important underlying inte

121 o histologic grade, primary versus recurrent disease status, and response, determined with integrated

122 scores overall and in multiple demographic, disease status, and study subgroups.

123 pt to physiological variables of blood flow, disease status, and tissue architecture by accommodating

124 umber of sub-analyses based on gender, prior disease status, and treatment discontinuation.

125 evelopment of novel compounds, assessment of disease status, and treatment efficacy.

126 ips between microbiological characteristics, disease status, and treatment response.

127 lowed by linkage analysis with the redefined disease statuses, and whole genome and exome sequencing.

128 rrelation with rigorously confirmed cervical disease status, are sparse.

129 bacteriaceae abundances were associated with disease status as expected, but also with treatment and

130 a and controls combined were associated with disease status, as well as negatively correlated with th

131 gene-locus-specific methylation alterations, disease status, asbestos burden, and survival in this ra

132 single cytokine) in combination with subject disease status (asthma or COPD).

133 ulin use, renal function, and cardiovascular disease status at baseline.

134 keletal-related events, irrespective of bone disease status at baseline.

135 reatment selection, and the determination of disease status at diagnosis without subjecting patients

136 e survival (PFS), overall survival (OS), and disease status at first restaging.

137 We also present subgroup analyses of disease status at presentation (primary vs recurrent dis

138 We estimated trends in disease status at presentation to care and at ART initia

139 Disease status at sampling was assessed by gastroscopy,

140 ti-inflammatory drug-exacerbated respiratory disease status at screening, previous surgery at screeni

141 Disease status at start of conditioning and the level of

142 ore, donor-recipient HLA-match, disease, and disease status at transplantation (factors associated wi

143 e from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gen

144 , overlapped with genes found in GWAS of MDD disease status, autoimmune disease and inflammation, and

145 ccording to the presence of minimal residual disease status before transplantation.

146 ng for age, sex, race/ethnicity, and chronic disease status, both uncorrected refractive error (odds

147 multimodal biomarkers could predict not only disease status but also cognitive function to help eluci

148 We propose a novel definition of disease status by specifying PFBC into genetic, clinical

149 f live kidney donors at risk for ADPKD whose disease status cannot be established with certainty on t

150 ulmonary evaluation within 6.5 years defined disease status; cases had FEV(1) less than lower limit o

151 measure of current QoL, is less sensitive to disease status changes but might be useful in characteri

152 d from bcl-2 PCR-detectable to -undetectable disease status, compared with 36% in the control group.

153 ern" koala populations, by investigating the disease status, completeness of the KoRV genome and the

154 ules that were significantly correlated with disease status, composed primarily of genes associated w

155 by which selection of subjects according to disease status creates biased associations if common cau

156 ication of patient disease likelihood versus disease status defined by quantitative coronary angiogra

157 Disease status, determined in patients and relatives, re

158 Grade and disease status did not significantly affect histogram pa

159 ncreas, and prostate, makes determination of disease status difficult.

160 ve symptom control alone (1:1; stratified by disease status, disease site, duration of response to pr

161 andatory, taking into account comorbidities, disease status, donor selection, and effective nontransp

162 d whether there is any change of periodontal disease status during and after pregnancy.

163 tcome and for longitudinal monitoring of the disease status during the maintenance period.

164 e-specified conceptual framework for health: disease status, effectiveness, safety, function, knowled

165 t lymphoma subtypes, with pretransplantation disease status emerging as the most important predictor

166 Subgroup analysis of end-stage renal disease status failed to reveal any association.

167 cumulative mortality by diabetes and kidney disease status for 15,046 participants in the Third Nati

168 tly increases the prediction accuracy of the disease status for three of the four datasets.

169 y derived biomarkers to identify periodontal disease status from whole saliva and plaque biofilm.

170 cells (CTC) offer great potential to monitor disease status, gauge prognosis, and guide treatment dec

171 Controls were matched for disease, disease status, graft type, patient age, and transplanta

172 ut their phenotype and function in different disease status have not been well studied.

173 ate (SDS)-soluble Abeta were able to predict disease status; however, SDS-soluble Abeta was a better

174 s is underlined by the correct prediction of disease status in 94-97% of cases.

175 e PET scans predicted relapsed or refractory disease status in a cohort of 251 patients with stage I-

176 ay serve as a biomarker of prior and current disease status in AN.

177 ication, and autoantigen gene expression and disease status in ANCA-associated vasculitis, we measure

178 each of these traits were utlized along with disease status in bivariate linkage analysis.

179 eported that urinary ADAM12 is predictive of disease status in breast cancer patients and that ADAM12

180 I would be able to monitor and differentiate disease status in dystrophic muscle.

181 because cosegregation of rare variation and disease status in families can amplify association signa

182 how that MTV provides a sensitive measure of disease status in individual patients with multiple scle

183 an adjunct to standard methods of monitoring disease status in MBC.

184 re sensitive prognostic tools for monitoring disease status in nasopharyngeal carcinoma (NPC) patient

185 isk for schizophrenia are also predictive of disease status in our data.

186 d with schizophrenia significantly predicted disease status in our sample (p = 5 x 10(-14)) and expla

187 f disease categories, treatment methods, and disease status in patients from across different geograp

188 Diet may play a role in disease status in patients with inflammatory bowel disea

189 dels performed on the training set predicted disease status in the testing set; median areas under th

190 However, assessing disease status in these animals has required time-consum

191 esents a new blood test to aid assessment of disease status in thyroid cancer follow-up.

192 phospholipase D3; Val232Met) segregated with disease status in two independent families and doubled r

193 therefore vital to have knowledge about the disease status in wild boar.

194 ause (if postmenopausal), and cardiovascular disease status (including coronary heart disease and str

195 he red module was negatively correlated with disease status, involving mostly nominally down-regulate

196 esigned to compare cases and controls, where disease status is modeled as a function of RNA-Seq reads

197 Simple permutation of disease status is unacceptable for resolving this issue

198 a genome or connectome has information about disease status, is increasingly important.

199 ess acknowledgment, recognition of incurable disease status, knowledge of the advanced stage of the d

200 confounders, including demographic factors, disease status, lifestyle, and dietary intakes, higher p

201 across a variety of tissues under different disease status, making computational identification of e

202 c meta-immunological profile associated with disease status may contribute to our understanding of th

203 therapeutic failure in the minimal residual disease status may relate to an incomplete understanding

204 Randomization was stratified by disease status (measurable v nonmeasurable), prior bevac

205 Disease status measures accounted for 62-72% of the vari

206 od with cardiometabolic function and chronic disease status more than 40 years later (in 2005-2007).

207 The phenotype can be univariate disease status, multivariate responses and even high-dim

208 r than the entire set of SNPs that modulated disease status (n = 14,751).

209 was a significant predictor of C. neoformans disease status (odds ratio, 5.5; P = .03).

210 Determining the disease status of badger social groups requires multiple

211 (PET) imaging is a key modality to evaluate disease status of brain tumors.

212 le information regarding the development and disease status of cells.

213 Antiviral efficacy was unrelated to the disease status of each animal, the protein from which th

214 umed that families were ascertained with the disease status of family members, and incorporation of t

215 'clean seed' and pesticide on crop yield and disease status of individual fields with varying levels

216 ial identifiers, or to information about the disease status of individual subscribers (although these

217 The TI is powerful in predicting the disease status of patients with metabolic disorders and

218 ures relating to the biological condition or disease status of samples but it also can accurately det

219 nction was used to determine the Parkinson's disease status of the A53T carriers.

220 information that can be used to predict the disease status of the examined biological tissue.

221 the cell layer regardless of host species or disease status of the host.

222 of the drug dose and release kinetics to the disease status of the treated vessel.

223 able patient factors such as distribution of disease, status of the limb, comorbid conditions, and co

224 There were no direct effects of disease status on DEE or RMR; however, there was a signi

225 ls were used to investigate the influence of disease status on systemic vascular disease and cerebral

226 We assessed familial disease status on the basis of self-reported family hist

227 athy, and nephropathy) and peripheral artery disease status on the risk of incident amputation events

228 ents, as well as the impact of prior chronic disease status on these functional outcomes.

229 esistance genes exists and is independent of disease status or antibiotic exposure.

230 gh to detect clinically important changes in disease status or effects of treatment.

231 well preserved in the lungs, irrespective of disease status or HIV coinfection.

232 e found no expression differences related to disease status or marker genotype for the other two gene

233 Biomarkers can be used to characterize disease status or predict disease behavior.

234 NA repair is related to individual genetics, disease status or progression and other environmental fa

235 the changing biological conditions, such as disease status or tissue developmental stages.

236 dels that predict either a categorical (i.e. disease status) or quantitative (i.e. cholesterol levels

237 estinal inflammation, longitudinally monitor disease status, or detect dysplastic changes in patients

238 cantly by gender, age (>/=40 vs. <40 years), disease status (OSD vs. control), order of administratio

239 his included questions related to treatment, disease status, other long-term conditions (LTCs), gener

240 tomic and functional stability in ocular VHL disease status over a mean follow-up of 8.2 +/- 4.0 year

241 was predictive of preclinical and overt HCM disease status (P < .01).

242 elated with PD and CAL regardless of patient disease status (P <0.001).

243 ion profiles in blood at baseline and future disease status (P = 2.0 x 10(-16)).

244 s non-activated vs and unknown) and visceral disease status (present vs absent).

245 CpG loci were independently associated with disease status (Q < 0.05).

246 sensitising platinum-based chemotherapy, and disease status (recurrent or persistent vs metastatic).

247 , busulfan, and melphalan group by sex, age, disease status, refractory to both proteasome inhibitors

248 eady survived, and for the patient's present disease status relative to recurrence.

249 s useful for monitoring individual change in disease status, selecting patients for therapy, and asse

250 acting factors including season, group size, disease status, sex, age, body mass and body fat.

251 ression trait attributable to differences in disease status, sex, cell or tissue type, ancestry, gene

252 mily history and either confirmed or unknown disease status should be monitored for hypertension (pre

253 s careful consideration and understanding of disease status, stage of pregnancy, FDA classification a

254 ing age, sex, Ann Arbor disease stage, bulky disease status, standardized uptake values (SUVs) on pos

255 and adjusted for age, lymphoma subtype, and disease status, survival was lower after UCB transplanta

256 ells are better correlates of Ag load (i.e., disease status) than of protection.

257 ta samples belong to different classes (e.g. disease status), the relationships may exhibit class-spe

258 imouse antibody response, and the enrollment disease status, the concordance index was 0.704.

259 aim, we address regional and local COVID-19 disease status, the role of viral screening and serologi

260 dily available information about disease and disease status to categorize patients into 4 risk groups

261 se of sensitive techniques for assessment of disease status to inform evidence-based decisions on opt

262 which are ideal for continuous monitoring of disease status, to optical spectroscopy and state-of-the

263 fference in the age, laterality, disease, or disease status (treatment naive vs. previously treated)

264 Irrespective of disease status, two CD46 variants were associated with r

265 or associations between genetic variants and disease status, typically via logistic regression.

266 based on acute kidney injury/chronic kidney disease status, underpinning the heterogeneity of fluid

267 In all participants, irrespective of their disease status, walking in Hyde Park led to an increase

268 Minimal residual disease status warrants consideration as an early measur

269 Disease status was assessed at baseline, 9 weeks, 18 wee

270 bel vedolizumab at weeks 0 and 2 (cohort 2); disease status was assessed at week 6.

271 Postoperative disease status was assessed endoscopically according to

272 as measured using a reporter cell assay, and disease status was assessed using the Disease Activity S

273 ffected," and "recovered." "Highly affected" disease status was associated with clinical complaints (

274 n from 8 CMR biomarkers; an index of chronic disease status was derived by assessing 8 chronic diseas

275 Atopic disease status was determined based on International Cla

276 Disease status was determined by using Global initiative

277 wed a certain degree of misclassification of disease status was developed to facilitate the identific

278 The periodontal disease status was measured by the mean clinical attachm

279 The determination of minimal-residual-disease status was more informative.

280 The association with disease status was most obvious for Pi (odds ratio [OR]:

281 After 2 courses, disease status was nonactive (n = 2), better (n = 23), o

282 Celiac disease status was not associated with overall survival.

283 Disease status was reassessed by CTC count (> or = 5 vs.

284 Peri-implant disease status was significantly associated with the sub

285 spouses, the concordance between the chronic disease status was striking.

286 onal grey matter density, age, education and disease status, we tested the association of regional gl

287 e predictive values for reported periodontal disease status were 56.2%, 78.8%, 32.8%, and 90.7%, resp

288 Health-related quality of life (HRQOL) and disease status were collected after 3 to 6 months.

289 Differences according to periodontal disease status were determined by analysis of variance w

290 At the patient level, only FasL and disease status were significantly correlated (P <0.05).

291 Survival and disease status were updated to February 2012.

292 to the stratification by, or enrichment for, disease status when testing associations between genetic

293 ians consider deprivation status, as well as disease status, when making decisions about treatments,

294 d CR1 expression levels were associated with disease status, where elevated expression levels were as

295 their relative information contribution to a disease status, which is different from the usual tag SN

296 change to a SNP might change an individual's disease status, which served as a calibration for each a

297 a set of possible temporal patterns of true disease status, whose prior probability was a function o

298 3 subgroups using discriminant analysis, or disease status with a binary assessment of sputum IL-1be

299 e associations between the OCTA measures and disease status within each retinal layer.

300 Peripheral biomarkers related to disease status would be extremely valuable for assessing